Background: Eravacycline is a novel, fully synthetic fluorocycline antibiotic of the tetracycline class with broad-spectrum activity in development for the treatment of multidrug-resistant (MDR) infections. Eravacycline has recently completed two Phase 3 studies for the treatment of complicated intraabdominal infections (cIAI) and complicated urinary tract infections (cUTI).
MIC determination
Minimum inhibitory concentration (MIC) endpoints were determined by broth microdilution according to CLSI guidelines (1) .
Quality control testing was performed each day of testing as specified by the CLSI using Escherichia coli ATCC 25922 and E. coli ATCC 35218.
Antibiotic susceptibility was determined using CLSI breakpoints (2) , with the exception of tigecycline where FDA breakpoints were used (3).
Multidrug-resistant (MDR) was defined as resistant to 3 or more of the following antibiotics: cefepime/ceftazidime/ceftriaxone (any one), gentamicin, imipenem, levofloxacin, piperacillintazobactam or tetracycline.
Methods and Materials n
A breakdown of the 4,462 Enterobacteriaceae collected by country of origin is shown in Table 1 .
n Summary MIC data for eravacycline against all Enterobacteriaceae and individual species where N ≥20, including MDR strains, are given in Table 3 .
n Eravacycline MIC 90 values ranged from 0.25 -4 µg/ml against MDR isolates from both Europe and the USA.
n Summary susceptibility and MIC data for eravacycline and comparators against all isolates combined and those from Europe and the USA, including MDR strains, are shown in Tables 2, 3 and 5.
n A comparison of ratio of tigecycline versus eravacycline MIC is shown in Figure 1 .
Results
n Against a total of 4,462 Enterobacteriaceae clinical isolates, eravacycline exhibited the lowest MIC 90 of 2 µg/ml (equal to cefepime and tigecycline) compared with antibiotics in the testing panel.
n Eravacycline had a lower MIC distribution than tetracycline or tigecycline, with 64% of isolates having an eravacycline MIC ≥2-fold lower than tigecycline.
n Eravacycline in vitro activity was similar against isolates from the USA and Europe.
n The MDR phenotype had little or no effect on eravacycline MIC.
n These data along with data from the recently completed Phase 3 trials will be used in determining breakpoints for eravacycline.
n Eravacycline exhibited potent in vitro activity against the majority of isolates, including MDR strains.
Introduction Figure 1. Ratio of Tigecycline MIC and Eravacycline MIC (all isolates).
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